117216 20230519145553.0 doi 10.1016/j.vaccine.2021.06.049 sideral 126758 ART-2021-126758 eng Martín, C. Universidad de Zaragoza (orcid)0000-0003-2993-5478 MTBVAC, a live TB vaccine poised to initiate efficacy trials 100 years after BCG 2021 Access copy available to the general public Unrestricted At its 100th birthday of its first administration to a newborn, BCG has been (and continues being) an inspiration for the construction and development of hundreds of new TB vaccine candidates in the last two and a half decades. Today, 14 candidates are in clinical development inside the global TB vaccine pipeline. MTBVAC is one of these candidates. Based on a live-attenuated Mycobacterium tuberculosis clinical isolate, MTBVAC''s 25 years of vaccine discovery, construction and characterisation have followed Pasteur principles, and in the process, BCG has served as a reference gold standard for establishing the safety and protective efficacy of new TB vaccine candidates. MTBVAC, which contains the antigen repertoire of M. tuberculosis, is now poised to initiate Phase 3 efficacy trials in newborns in TB-endemic countries. BCG''s efficacy extends beyond that against TB, shown to confer heterologous non-specific immunity to other diseases and reduce all-cause mortality in the first months of life. Today, WHO recognises the importance that any new TB vaccine designed for administration at birth, should show similar non-specific benefits as BCG vía mechanisms of trained immunity and/or cross-reactivity of adaptive immune responses to other pathogens. Key recent studies provide strong support for MTBVAC''s ability of inducing trained immunity and conferring non-specific heterologous protection similar to BCG. Research on alternative delivery routes of MTBVAC, such as a clinically feasible aerosol route, could facilitate vaccine administration for long-term TB eradication programmes in the future. © 2021 The Author(s) info:eu-repo/grantAgreement/EC/H2020/643381/EU/TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development/TBVAC2020 This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No H2020 643381-TBVAC2020 info:eu-repo/grantAgreement/ES/MICINN/RTC-2017-6379-1 info:eu-repo/semantics/openAccess by-nd http://creativecommons.org/licenses/by-nd/3.0/es/ 4.169 2021 MEDICINE, RESEARCH & EXPERIMENTAL 73 / 140 = 0.521 2021 Q3 T2 IMMUNOLOGY 94 / 163 = 0.577 2021 Q3 T2 1.392 2021 Immunology and Microbiology (miscellaneous) 2021 Q1 Veterinary (miscellaneous) 2021 Q1 Public Health, Environmental and Occupational Health 2021 Q1 Infectious Diseases 2021 Q1 6.7 2021 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Marinova, D. Aguiló, N. Universidad de Zaragoza (orcid)0000-0001-7897-9173 Gonzalo-Asensio, J. Universidad de Zaragoza (orcid)0000-0001-8841-6593 1011 630 Universidad de Zaragoza Dpto. Microb.Ped.Radio.Sal.Pú. Área Microbiología 39, 50 (2021), 7277-7285 Vaccine VACCINE 0264-410X 1223458 http://zaguan.unizar.es/record/117216/files/texto_completo.pdf Versión publicada 2706197 http://zaguan.unizar.es/record/117216/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:117216 articulos driver 2023-05-18-15:52:22 ARTICLE